Skip to main content
. Author manuscript; available in PMC: 2021 Oct 12.
Published in final edited form as: ACS Biomater Sci Eng. 2020 Sep 10;6(10):5941–5958. doi: 10.1021/acsbiomaterials.0c01075

Figure 8. Administration of the dMP reduced markers of activation on DCs in dMP-draining lymph nodes.

Figure 8.

Twelve-week-old pre-diabetic NOD mice received aCD3 and dMP treatment at identical time points as in the prevention study and were euthanized at 20 weeks of age, prior to the sixth dMP injection. As before, MP injections were administered subcutaneously on the right side of the abdomen, proximal to the pancreas. (A) Ipsilateral dMP-draining lymph nodes (combined inguinal and axillary) were excised and stained for flow cytometry (n = 4–5/group). Mean fluorescent intesnsity (MFI) of CD80 (B), CD86 (C), and MHC-II (D) expression was characterized on Ly6G−CD11b+CD11c+ DCs. P-values (* ≤ 0.05, ** ≤ 0.01) were determined by one-way ANOVA with Tukey’s multiple comparison test. Significance in (C-D) is illustrated by pairwise comparisons between groups with flat bars (no treatment, low-dose aCD3, and ultra-low dose aCD3 groups)against each group with curved bars (dMP OVA + control IgG, dMP, and low-dose aCD3 + dMP groups) (nine significant pairwise comparisons total). Data is represented by mean ± SEM. Full gating scheme – see Supplemental Figure 11.